CAR T-Cell Therapy: What It Is & How It Works

CAR T-cell therapy is an advanced cancer immunotherapy that uses genetically modified T-cells to identify and destroy cancer cells more effectively. It is primarily used for relapsed or treatment-resistant blood cancers such as leukaemia, lymphoma, and multiple myeloma. This guide explains how CAR T-cell therapy works, eligibility criteria, treatment timelines, side effects, recovery, success rates, and how it compares to chemotherapy and bone marrow transplant. It also highlights why India is emerging as a leading destination for affordable, world-class CAR T-cell treatment.

Table of Contents

• What is CAR T-Cell Therapy?
• Who Qualifies for CAR T-Cell Therapy?
• What Conditions Can CAR T-Cell Therapy Treat?
• How Does CAR T-Cell Therapy Work?
• CAR T-Cell Therapy Treatment Process Timeline
• What Happens Before I Have CAR T-Cell Therapy?
• What Happens During CAR T-Cell Therapy?
• What Happens After CAR T-Cell Therapy?
• CAR T-Cell Therapy Recovery Timeline
• Side Effects of CAR T-Cell Therapy
• What Are the Benefits of CAR T-Cell Therapy?
• How Successful Is This Treatment?
• CAR T-Cell Therapy vs Other Cancer Treatments
• CAR T-Cell Therapy Cost in India
• Why International Patients Choose India for CAR T-Cell Therapy
• When to See a Doctor

What is CAR T-Cell Therapy?

CAR T-cell therapy revolutionises cancer treatment by harnessing the body’s immunity to fight the disease. This innovative immunotherapy modifies a patient’s T-cells to recognise and attack cancer cells more effectively and is increasingly being integrated with advanced bone marrow transplant and cellular therapy programmes. The process involves extracting T-cells from the patient’s blood, genetically engineering them to produce Chimeric Antigen Receptors (CARs), and reinfusing them into the patient’s body.

This targeted approach offers significant advantages over traditional cancer treatments like chemotherapy and radiation, as it precisely eliminates cancer cells while sparing healthy ones, potentially reducing severe side effects.

Who Qualifies for CAR T-Cell Therapy?

Not all cancer patients are eligible for CAR T-cell therapy. The treatment is typically recommended for patients who meet specific clinical criteria. Your oncology team will evaluate multiple factors before determining suitability.

General Eligibility Criteria

• Cancer Type: Primarily indicated for certain B-cell blood cancers including ALL, DLBCL, mantle cell lymphoma, follicular lymphoma, and multiple myeloma.
• Treatment History: Patients must typically have relapsed after or be refractory to at least two prior lines of therapy.
• Age: Approved for paediatric and young adult patients (up to 25 years) for ALL; adult patients for lymphoma and myeloma indications.
• Performance Status: Patients must have adequate organ function and an ECOG performance status of 0–1 (able to carry out daily activities).
• Disease Burden: Active measurable disease is required; the disease must not be progressing so rapidly that manufacturing timelines cannot be met.
• Prior Transplant Status: Patients who have relapsed after an allogeneic stem cell transplant may be eligible, provided they do not have active graft-versus-host disease.

Who May Not Be Eligible

• Patients with active, uncontrolled infections.
• Those with severe organ dysfunction (cardiac, hepatic, renal, or pulmonary).
• Patients with active central nervous system involvement (varies by product).
• Those currently receiving systemic immunosuppressive therapy.
• Patients who cannot tolerate the 3–4 week manufacturing wait period due to rapidly progressive disease.

What Conditions Can CAR T-Cell Therapy Treat?

CAR T-cell therapy primarily treats certain blood cancers, including:

• Acute Lymphoblastic Leukaemia (ALL): Shows remarkable success in treating relapsed or refractory ALL in children and adults.
• Diffuse Large B-cell Lymphoma (DLBCL): Approved for treating relapsed or refractory DLBCL.
• Follicular Lymphoma: Currently under investigation as a potential treatment option.
• Multiple Myeloma: Researchers are studying its effectiveness for this condition.

Patients with relapsed blood cancers may also benefit from understanding bone marrow transplants and when bone marrow transplant is recommended for leukaemia. While CAR T-cell therapy has mainly focused on blood cancers, scientists actively explore its potential in treating solid tumours like breast, lung, and brain cancers.

Types of Cancers Treated with CAR T-Cell Therapy

How Does CAR T-Cell Therapy Work?

The CAR T-cell therapy process involves several steps:

• T-cell Collection: Doctors collect the patient’s T-cells through leukapheresis, separating them from other blood components.
• Genetic Engineering: Laboratory technicians modify the collected T-cells to express CARs on their surface, designed to recognise specific cancer cell antigens.
• T-cell Expansion: The genetically engineered CAR T-cells multiply in the laboratory to create many specialised cells.
• Conditioning Chemotherapy: Patients may undergo chemotherapy to deplete existing T-cells and create space for the new CAR T-cells.
• CAR T-cell Infusion: Doctors infuse the expanded CAR T-cells into the patient’s body through an IV line.
• Monitoring and Follow-up: The medical team monitors the patient for potential CAR T-cell therapy side effects and treatment effectiveness, conducting regular follow-up appointments and tests.
  
  

In some cases, CAR T-cell therapy may be used before or after autologous or allogeneic bone marrow transplant procedures depending on the patient’s disease status and response to treatment.

CAR T-Cell Therapy Treatment Process Timeline

Understanding the full treatment journey helps patients and families prepare. The following timeline outlines each phase from initial consultation to long-term follow-up:

What Happens Before I Have CAR T-Cell Therapy?

Before undergoing CAR T-cell therapy, patients go through several preparatory steps:

• Initial Evaluation: The medical team conducts a comprehensive evaluation to determine the patient’s suitability for the therapy.
• Apheresis: Doctors collect T-cells from the patient’s blood through leukapheresis.
• Conditioning Chemotherapy: Some patients receive chemotherapy to prepare their body for the CAR T-cell infusion.
• Supportive Care: The healthcare team provides measures to manage potential side effects & ensure overall well-being during treatment.

What Happens During CAR T-Cell Therapy?

During the CAR T-cell therapy procedure:

• T-cell Engineering: Laboratory specialists genetically modify the collected T-cells to express CARs.
• T-cell Expansion: The modified T-cells multiply in the laboratory to ensure a sufficient number for infusion.
• CAR T-cell Infusion: Doctors infuse the expanded CAR T-cells into the patient’s body through an IV line.
• Monitoring and Support: The healthcare team monitors the patient for potential side effects and provides necessary supportive care.

What Happens After CAR T-Cell Therapy?

After receiving CAR T-cell therapy:

• Recovery Period: Patients may experience fatigue, fever, and flu-like symptoms as their body responds to the treatment.
• Follow-up Appointments: Regular check-ups help monitor progress and response to therapy.
• Ongoing Monitoring: The medical team continues to watch for signs of disease recurrence or long-term side effects.
• Supportive Care: Patients may receive additional care measures for recovery and overall well-being.
• Long-term Follow-up: Regular appointments monitor for potential long-term effects and ensure continued treatment effectiveness.

CAR T-Cell Therapy Recovery Timeline

Recovery from CAR T-cell therapy is a gradual process that varies by individual. The following outlines what patients can generally expect:

Side Effects of CAR T-Cell Therapy

While CAR T-cell therapy shows remarkable success, it can lead to potentially severe side effects:

• Cytokine Release Syndrome (CRS): A potentially life-threatening condition causing high fever, chills, low blood pressure, and respiratory distress.
• Neurological Toxicities: Some patients may experience confusion, delirium, seizures, or speech and language impairments.
• Infections: The treatment can weaken the immune system, increasing infection susceptibility.
• Anaemia and Neutropenia: The therapy may decrease red blood cells and specific white blood cells, increasing infection risk.
• Tumour Lysis Syndrome: Rapid cancer cell death can lead to kidney failure and other metabolic disturbances.
• Graft-versus-host Disease (GvHD): In some cases, CAR T-cells may attack healthy cells, leading to GvHD.

The medical team closely monitors and manages these side effects, varying in severity and duration among patients.

Cytokine Release Syndrome (CRS): Severity Grading

CRS is the most common serious side effect of CAR T-cell therapy. Understanding its severity grades helps patients and caregivers recognise symptoms early:

Most CRS episodes are Grade 1–2 and resolve with standard management. Early recognition and prompt treatment with tocilizumab have significantly improved CRS outcomes.

What Are the Benefits of CAR T-Cell Therapy?

Despite potential side effects, CAR T-cell therapy offers significant benefits:

• Targeted Treatment: It specifically targets cancer cells while sparing healthy ones, reducing the risk of severe side effects associated with traditional therapies.
• Personalised Approach: The therapy uses the patient’s own genetically modified T-cells to attack their specific cancer cells.
• Potential for Durable Remission: Some patients experience long-lasting remissions, even with advanced or relapsed cancers that haven’t responded to other treatments.
• Improved Quality of Life: By targeting cancer cells more effectively, CAR T-cell therapy may reduce the disease burden and ongoing treatment needs.
• Ongoing Research: Scientists continuously work to improve the safety and efficacy of CAR T-cell therapy and explore its potential in treating a more comprehensive range of cancers.

How Successful Is This Treatment?

The success rate of CAR T-cell therapy varies depending on the cancer type, specific CAR T-cell product, and individual patient characteristics. Clinical trials and real-world experience have shown promising results:

• Acute Lymphoblastic Leukaemia (ALL): Up to 90% of patients achieve remission after treatment in clinical trials for relapsed or refractory ALL.
• Diffuse Large B-Cell Lymphoma (DLBCL): Response rates range from 40% to 60% for patients with relapsed or refractory DLBCL, with some achieving long-lasting remissions.
• Multiple Myeloma: Though research is ongoing, early clinical trials show response rates ranging from 30% to 70%.

Various factors influence success rates, including cancer type, overall health, and previous treatments. The healthcare team evaluates each case individually to provide guidance on potential outcomes.

Success Rates by Cancer Type

The following table provides a detailed breakdown of response and survival data from published clinical trials and real-world studies:

CAR T-Cell Therapy vs Other Cancer Treatments

Patients often want to understand how CAR T-cell therapy compares to other established treatment options. The following comparisons highlight key differences:

CAR T-Cell Therapy vs Chemotherapy

CAR T-Cell Therapy vs Bone Marrow Transplant (BMT)

CAR T-Cell Therapy vs Targeted Therapy

CAR T-Cell Therapy Cost in India

CAR T-cell therapy cost is one of the most important considerations for patients and families. India has emerged as a significantly more affordable destination for this cutting-edge treatment compared to Western countries.

What Does the Cost Include?

• Pre-treatment evaluation and diagnostic workup
• Leukapheresis (T-cell collection)
• CAR T-cell manufacturing and quality testing
• Conditioning chemotherapy
• CAR T-cell infusion
• Hospital stay during the acute monitoring period (7–14 days)
• ICU management if CRS occurs
• First response assessment (Day 28–90 scans and biopsy)

Additional costs may include bridging therapy, extended hospital stays for complications, immunoglobulin replacement therapy, and long-term follow-up visits. Patients are advised to discuss a detailed cost estimate with the treatment centre prior to starting therapy.

Why International Patients Choose India for CAR T-Cell Therapy

India is rapidly becoming a preferred destination for CAR T-cell therapy, offering a combination of world-class medical expertise, advanced infrastructure, and significant cost savings. Key reasons patients choose India include:

• Cost Savings of 70–90%: CAR T-cell therapy in India costs a fraction of what patients pay in the US, UK, or Europe, without compromising quality.
• NABH-Accredited Hospitals: India’s leading cancer centres meet international quality and safety standards.
• Experienced Haematology Teams: Indian oncologists and BMT physicians are trained at leading global institutions and have extensive experience in cellular therapies.
• Shorter Wait Times: Patients can often begin the treatment process within 1–2 weeks of arriving in India, compared to months-long waiting lists in Western countries.
• India-Manufactured CAR T Products: India has developed indigenous CAR T-cell products (such as NexCAR19 by ImmunoACT), approved by CDSCO, making the therapy more accessible and affordable.
• Comprehensive International Patient Support: Leading hospitals provide end-to-end services including visa assistance, airport transfers, accommodation, interpreter services, and dedicated international patient coordinators.
• Medical Tourism Infrastructure: Bangalore, Mumbai, Delhi, and Chennai have well-established medical tourism ecosystems with experience handling international patients.

International patients can also explore the complete Patient Journey at SPARSH Hospitals- Global Care to understand visa assistance, accommodation support, and treatment coordination services.

When to See a Doctor

Consider consulting a doctor about CAR T-cell therapy in the following situations:

• Relapsed or Refractory Cancer: If your cancer has returned after initial treatment or doesn’t respond to standard therapies.
• Aggressive or Advanced Cancer: CAR T-cell therapy may offer a potentially curative option for certain types of aggressive or advanced cancers.
• Lack of Response to Standard Treatments: If you haven’t responded well to traditional cancer treatments.
• Participation in Clinical Trials: If you’re interested in joining clinical trials investigating CAR T-cell therapy for your specific cancer type.
• Second Opinion: Seeking a second opinion from a specialist or comprehensive cancer centre with CAR T-cell therapy expertise can be beneficial.

Always thoroughly discuss with your healthcare team to determine if CAR T-cell therapy suits your specific situation.

Conclusion

If you’re looking for a successful bone marrow transplant, it is crucial to consult with the Best Bone Marrow Transplant Doctors in Bangalore. These experienced professionals offer expert care, ensuring the best possible treatment and recovery. Seeking the right specialist for your health can make a huge difference in your journey to recovery. Make sure to choose the right doctor for the best outcomes.

While many people consider it as cancer-free CAR T-cell therapy, particularly in treating certain blood cancers, it’s crucial to be aware of adverse effects and risks. Close monitoring and supportive care from a specialised healthcare team are essential throughout the treatment process.

Ongoing research continues to expand CAR T-cell therapy applications, with clinical trials exploring its potential in treating solid tumours and other cancer types. This personalised and targeted approach represents a promising frontier in the fight against cancer, offering new hope and possibilities for patients and their families.

If you or a loved one has received a cancer diagnosis and wants to explore CAR T-cell therapy, we encourage you to schedule a consultation with our expert team at SPARSH Hospitals – Global Care, BMT Hospital in Bangalore. You can also explore the hospital’s comprehensive Oncology Speciality services for advanced cancer treatment and care.